Year: 2025
Type: article
Abstract: Bülent ÖzlekHeart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) frequently coexist, sharing key risk factors such as aging, obesity, diabetes, and hypertension.1,2 When present together, they contribute synergistically to increased morbidity and mortality.AF is observed in 40%-60% of HFpEF patients and is associated with worsened prognosis due to heightened symptom burden, increased hospitalizations, and elevated thromboembolic risk.Despite advancements in HFpEF management, strategies to prevent newonset AF or reduce its recurrence remain inadequate.Recently, sodium-glucose cotransporter-2 inhibitors (SGLT2i) have become a cornerstone in HFpEF treatment, improving the outcomes regardless of the diabetes status. 3 Their pleiotropic cardiometabolic effects have generated growing interest in their potential role in AF prevention.
Source: Balkan Medical Journal
Author: Bülent Özlek
Institution: Muğla University
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4413811955